A real-world study presented at the virtual 2021 ASCO Annual Meeting evaluated prostate-specific antigen pattern progression and its association with overall survival (OS) among patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide or abiraterone. In a real-world setting, prostate-specific antigen value is used among practitioners to Read more…
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer. “In 2020 ASCO recommended that all women with epithelial ovarian cancer have germline testing for BRCA1/2 mutations, and those without a germline pathogenic variant should have somatic tumor testing, to Read more…
More than half of patients with metastatic castration-sensitive prostate cancer (mCSPC) did not receiveandrogen deprivation therapy (ADT) plus docetaxel or ADT plus novel hormonal therapies as first-line treatment in 2019, even though these regimens are associated with improved survival compared to ADT alone, according to a study presented at the Read more…
This study evaluated the cost-effectiveness of prophylactic cranial irradiation compared with magnetic resonance imaging (MRI) surveillance in this patient population. Cost-effectiveness of the treatment approaches were based on currently available evidence and in the context of the proposed Centers for Medicare & Medicaid Services alternative payment model. A Markov state Read more…
Multiple myeloma (MM) remains an incurable disease despite incorporation of novel agents. Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor is approved for some hematologic malignancies but not yet for MM, although clinical trials have shown efficacy in patients with MM particularly those harboring t(11;14). Venetoclax demonstrates encouraging activity in heavily-treated Read more…
Previous literature has explored the beneficial relationship between physical activity and quality of life improvement (QOL) sin patients with MM. A study published in BMJ Supportive and Palliative Care found that physically active MM survivors reported higher health-related QOL (HRQOL), including significant improvements in fatigue (P=0.002) and reduced treatment-related adverse effects (P=0.001), Read more…
Incidence of multiple myeloma (MM) has more than doubled globally since 1990, according to an analysis published in BMC Cancer. In order to evaluate the global disease burden, the investigators utilized 2019 data from the Global Burden of Disease study to calculate incidence, mortality, and disability adjusted life-years associated with MM. Read more…
Mayo Clinic today recognized the debut of a groundbreaking multi-cancer early cancer detection (MCED) test called Galleri™ that can detect more than 50 types of cancers through a simple blood draw. The Galleri test is intended to complement U.S. guideline-recommended cancer screenings. Mayo Clinic Oncologist Minetta Liu, M.D. was involved in the Read more…
More than a third of patients who progressed on osimertinib (Tagrisso) therapy for EGFR-positive non–small cell lung cancer (NSCLC) had a response to the combination of amivantamab (Rybervant) plus lazertinib, according to results of a cohort of the CHRYSALIS trial (NCT02609776) presented during the 2021 ASCO Annual Meeting. Biomarker analysis in Read more…
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a Read more…